11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 10.04.2026 Expectation: 500 pips
AUDCAD flashes short-term buy signal
Yesterday at 11:27 AM 26
Period: 10.04.2026 Expectation: 800 pips
GBPUSD is poised to resume decline after short-term bullish momentum
Yesterday at 11:23 AM 26
Period: 29.05.2026 Expectation: 2000 pips
Selling USDCAD with 1.37250 target
Yesterday at 10:06 AM 17
Period: 30.04.2026 Expectation: 1300 pips
Investing in SPX during correction with 6,700 in sight
Yesterday at 07:33 AM 11
Brent sell
Period: 10.04.2026 Expectation: 850 pips
Brent crude pullback is coming as geopolitical premium fades
Yesterday at 06:51 AM 32
Period: 30.04.2026 Expectation: 850 pips
Selling EURUSD down to 1.1490
Yesterday at 04:12 AM 18
Go to forecasts